Mucosa Associated Lymphoid Tissue Lymphoma

• MALT lymphoma is an indolent non-Hodgkin lymphoma arising from mucosa-associated lymphoid tissue.
• It is often linked to chronic inflammation, frequently triggered by bacterial infections like H. pylori.
• Symptoms vary widely depending on the affected organ, and diagnosis typically involves biopsy and imaging.
• Treatment strategies range from antibiotic therapy for H. pylori-positive cases to radiation, chemotherapy, or immunotherapy.

What is Mucosa Associated Lymphoid Tissue Lymphoma (MALT Lymphoma)?

Mucosa Associated Lymphoid Tissue Lymphoma (MALT lymphoma) is a distinct subtype of non-Hodgkin lymphoma that develops in the mucosa-associated lymphoid tissue (MALT). This specialized lymphoid tissue is not typically present in healthy mucosal linings but can develop in response to chronic inflammation or infection. MALT lymphoma is generally considered an indolent, or slow-growing, lymphoma, meaning it progresses at a more gradual pace compared to aggressive lymphomas. It can occur in various parts of the body, with the stomach being the most common site, but it can also affect the salivary glands, lungs, thyroid, skin, and other mucosal surfaces. The presence of MALT lymphoma indicates an abnormal proliferation of B-lymphocytes within these acquired lymphoid tissues.

Causes, Symptoms, and Diagnosis of MALT Lymphoma

The causes of mucosa associated lymphoid tissue lymphoma are frequently linked to chronic inflammatory conditions, often driven by persistent infections or autoimmune diseases. A prominent example is gastric MALT lymphoma, which is strongly associated with chronic infection by the bacterium Helicobacter pylori (H. pylori). This bacterium induces a sustained inflammatory response in the stomach lining, leading to the formation of MALT, which can then undergo malignant transformation. Other associations include Sjögren’s syndrome with salivary gland MALT lymphoma and Hashimoto’s thyroiditis with thyroid MALT lymphoma. The exact mechanisms by which chronic inflammation leads to lymphoma are complex but involve continuous immune stimulation and genetic changes in B-cells.

MALT lymphoma symptoms and diagnosis are highly variable, depending on the primary site of involvement. For instance, gastric MALT lymphoma may present with symptoms such as indigestion, abdominal pain, nausea, or weight loss. Pulmonary MALT lymphoma might cause a persistent cough or shortness of breath, while salivary gland involvement could lead to painless swelling. According to the Lymphoma Research Foundation, MALT lymphoma accounts for approximately 5-8% of all non-Hodgkin lymphomas, making it one of the more common indolent subtypes.

Diagnosis typically involves a combination of methods:

• Endoscopy with biopsy: Essential for confirming the diagnosis and identifying the specific subtype of lymphoma, particularly for gastrointestinal involvement.
• Imaging studies: Computed tomography (CT) scans, positron emission tomography (PET) scans, and endoscopic ultrasound help determine the extent of the disease and identify other affected areas.
• Blood tests: May assess overall health and organ function, though specific lymphoma markers are less common for MALT lymphoma in blood.
• Molecular testing: Biopsy samples are often analyzed for specific genetic translocations, such as t(11;18)(q21;q21), which can influence prognosis and treatment choices.

MALT Lymphoma Treatment Options

The MALT lymphoma treatment options are tailored to the specific location of the lymphoma, its stage, and the patient’s overall health. Given its indolent nature, a “watch and wait” approach may be considered for very localized, asymptomatic cases. For gastric MALT lymphoma associated with H. pylori infection, antibiotic therapy is often the first line of treatment and can lead to complete remission in a significant number of patients by eradicating the infection. This highlights the unique link between infection and this specific lymphoma subtype.

Other common treatment modalities include radiation therapy, often used for localized disease, especially in non-gastric sites, offering high rates of local control. Chemotherapy may be employed for more widespread disease or cases that do not respond to initial therapies, with regimens typically less intensive than those for aggressive lymphomas. Immunotherapy, such as monoclonal antibodies like rituximab, which targets CD20 on B-lymphocytes, is frequently used alone or in combination with chemotherapy, particularly for advanced or refractory cases. Surgery is rarely the primary treatment for MALT lymphoma, but it may be considered in specific circumstances, such as to remove a localized tumor causing obstruction or bleeding, or for diagnostic purposes. The choice of treatment is a multidisciplinary decision, often involving oncologists, gastroenterologists, and radiation oncologists, to ensure the most effective and least toxic approach.